Quality-of-Life Outcomes After Transcatheter Aortic Valve Implantation in a “Real World” Population: Insights From a Prospective Canadian Database

• DOI: 10.1016/j.cjco.2021.04.006
• Publication Date: 2021-04-24T05:38:33Z
• Authors: Sandra B. Lauck; Maggie Yu; Lillian Ding; Sean Hardiman; Daniel Wong; Janarthanan Satha...; Jian Ye; Albert Chan; Steven Hodge; Simon Robinson; David A. Wood; John G. Webb
• Keywords: 03 medical and health sciences; 0302 clinical medicine; RC666-701; Diseases of the circulatory (Cardiovascular) system; Original Article

BackgroundDocumentation of quality life (QOL) patients after transcatheter aortic valve implantation (TAVI) is a Canadian Cardiovascular Society indicator. National results have not been reported to date.MethodsWe conducted an observational cohort study including all TAVI patients, irrespective surgical risk, treated between January 2016 and June 2019 as documented in the British Columbia Registry. QOL was measured at baseline, 30 days, 1 year, using Kansas City Cardiomyopathy Questionnaire overall score (KCCQ-OS). We used linear regression modelling examine factors associated with 30-day changes QOL, logistic identify predictors sustaining poor outcome, Cox ascertain risk estimates effect on 1-year mortality.ResultsThe included 1706 (742 women [43.5%]); median age 83 years (interquartile range [IQR]: 77, 86). Median (IQR) baseline KCCQ-OS 45 (28.2, 67), indicating severe impairment. Patients alive year (91.3%) mean improvement 24.1 (95% confidence interval [CI], 22.7-25.6) points which sustained (25.3; 95% CI, 23.8, 26.8). Older age, lower health status, gradient, hemoglobin, atrial fibrillation, non-transfemoral access were worse QOL. At 65% had favorable outcome; additional for mortality (8.7%) male sex, New York Heart Association Class IV, pulmonary renal disease, diabetes, in-patient status.ConclusionsTAVI significant early year. The inclusion can support treatment decisions patient-centred evaluation.